PatientsVille.com Logo

TREMOR and Clonidine

PatientsVille

TREMOR Symptoms and Causes

Tremors are unintentional trembling or shaking movements in one or more parts of your body. Most Tremors occur in the hands. You can also have arm, head, face, vocal cord, trunk, and leg Tremors. Tremors are most common in middle-aged and older people, but anyone can have them.

The cause of Tremors is a problem in the parts of the brain that control muscles in the body or in specific parts of the body, such as the hands. They commonly occur in otherwise healthy people. They may also be caused by problems such as

  • Parkinson's disease
  • Dystonia
  • Multiple sclerosis
  • Stroke
  • Traumatic brain injury
  • Alcohol abuse and withdrawal
  • Certain medicines

Some forms are inherited and run in families. Others have no known cause.

There is no cure for most Tremors. Treatment to relieve them depends on their cause. In many cases, medicines and sometimes surgical procedures can reduce or stop Tremors and improve muscle control. Tremors are not life threatening. However, they can be embarrassing and make it hard to perform daily tasks.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for TREMOR

TREMOR treatment research studies

Clonidine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Clonidine Side Effects

Blood Pressure Increased (136)
Completed Suicide (121)
Hypotension (117)
Hypertension (95)
Product Adhesion Issue (72)
Headache (68)
Product Substitution Issue (64)
Dizziness (62)
Dyspnoea (55)
Product Quality Issue (54)
Poisoning (53)
Bradycardia (52)
Death (49)
Cardiac Arrest (47)
Nausea (45)
Somnolence (43)
Dry Mouth (42)
Fatigue (41)
Anxiety (40)
Asthenia (39)
Overdose (38)
Pain (35)
Agitation (34)
Feeling Abnormal (32)
Suicide Attempt (31)
Lethargy (31)
Depression (30)
Heart Rate Increased (30)
Sinus Bradycardia (30)
Loss Of Consciousness (29)
Hypertensive Crisis (29)
Vomiting (28)
Respiratory Arrest (28)
Chest Pain (26)
Blood Pressure Decreased (25)
Syncope (25)
Convulsion (24)
Cardio-respiratory Arrest (24)
Rash (23)
Application Site Rash (23)
Blood Pressure Inadequately Controlled (22)
Insomnia (22)
Cerebrovascular Accident (22)
Hyperhidrosis (21)
Accidental Overdose (20)
Tachycardia (20)
Application Site Pruritus (20)
Hypersensitivity (19)
Tremor (19)
Sedation (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After taking clonidine 0.1mg cut 9in half, for two dauys, twicw a day: it felt like a I had a terrible gastric ulcer. i TOOK IYT WITH A MEAL AND DRANK 10 OUNCES OF WATER. i took it again the next day with the same result. Do they

Anxiety and waking dreams about mouth. The dryness of mouth so annoying tha the reason for taking med not worth discomfort.

Head, ears, throat, too tired, hate to take it.....Dr. said it is a nasty pill but still prescribed it. also, constipation/ loose stools. stomach discomfort....leg / foot spasms at night

I am feeling drowsy,weak, and my heart is racing. is that suppose to happen?

I find this medication terrible. I dont know aboutanyone else but I have found that my body has become addictived to this drug. I have only been on this drug since June 18, 2010. I am on the patch 2mg plusone 1 mg tablet 2x per da

I just started on Clonidine for excessive sweating of the scalp and face, but also for insomnia. I had to take .3 mg to get sleepy. I woke up this morning with several canker like sores on the inside of my lips. Anyone else had this happen? I als

I started with taking 1 at bedtime .1mg then bp went up then went to .1 4 per day didn't last then tried Transdermal system this didn't stick to my skin result no medicine delivered i went thru withdraw ?

I take 0*1 mg Clonidine for high BP and have the sensation that my esophagus or chest muscles are spasming. Also my heart rate is accelerated. Are these expected side effects of this medication.

I take only a portion of a 0.1 mg Clonidine once a day. Since I have been taking this medicine, the have been times that my skin feels that needles are sticking in it---this is all over my body. Has anyone else had this happen? I don't know for su

My goodness. I believe every one of those persons talking about this medicine. It is so true and I've only been on it not even a month and I have all of those symptoms. I am so tired of falling asleep anywhere.

<span style='font-weight: bold;'><a href='http://sideeffects101.com/drug-side-effects/euglucon-hypoglycaemia.htm' rel='nofollow'>hypoglycaemia</a>, little bit of tremor, dosage was just 2.5mg and treated with diovan 80, celebrex 200

Did not know what was going on, panic attacks yesterday. muscle cramping and tremor, sleeplessness, its all here, going off of this. very scary

Feeling dizzy and lightheaded, headache, uneasy jaw, inner tremor

Hand tremor

Hi there...I stopped taking invega about 4 weeks ago ....i am also on 100mg of zoloft and 1.5 mg of clonazapam....ever since I stopped taking invega, I have developed this internal tremor...inability to sit still etc...will this go away? please help.

Hi: I have taken propranalol,80mg, for years and I am now taking 250 mg of primodone in AM and PM. I have found that it completely turns my stomach around and makes me very sleepy. I do take it for essential tremor but there is nothing like a vodka

I am using metycobal 500mg daily for familiar tremor will it benefit me

I do not know that my head has a tremor, family and working collegues notified me several times of it had a MR brain scan twice, a lesion was dedected on the left side of my frontal brain i am only 44 years old and the head tremor is becoming a rea

I had tremor, pain in all the parts of my body (especially neck, chest and legs), 'drunk sensation', and a very bad and brutal acceleration of my heart at 3am (which led me to the emergency service at the nearest hospital...). I felt sick, like havin

I have been off cytomel for 4 weeks and still have nervousness, tremor, muscle rigidity an sleep disturbances. When can I expect this to improve?

TREMOR Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
Conditions: Tremor;   Essential Tremor;   Parkinson Disease;   Radiosurgery;   Quality of Life
Intervention:
Outcome Measures: Quality of Life;   Severity of Tremor
2 Not yet recruiting Limb Cooling in Essential Tremor
Condition: Essential Tremor.
Intervention: Procedure: Limb Cooling Assessment of ET
Outcome Measures: Hand writing assessment battery on limb cooling at 60 minutes post-cooling;   Tremor rating scale on limb cooling at 40 minutes post-cooling;   Functional dexterity test on limb cooling at 60 minutes post-cooling;   Hand writing assessment battery on limb cooling at 15 minutes post-cooling;   Hand writing assessment battery on limb cooling at 40 minutes post-cooling;   Tremor rating scale on limb cooling at 15 minutes post-cooling;   Functional dexterity test on limb cooling at 15 minutes post-cooling;   Functional dexterity test on limb cooling at 40 minutes post-cooling;   Tremor rating scale on limb cooling at 60 minutes post-cooling;   Effect of limb cooling on the physiological characteristics of essential Tremors.
3 Recruiting Effects of Octanoic Acid for Treatment of Essential Voice Tremor
Conditions: Essential Voice Tremor;   Vocal Tremor;   Voice Tremor;   Essential Tremor of Voice
Intervention: Drug: Octanoic acid
Outcome Measures: Pre- to post-treatment change in the acoustic characteristics of voice tremor;   Pre- to post-treatment change in the auditory-perceptual characteristics of voice tremor
4 Not yet recruiting The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study
Conditions: Essential Tremor;   Parkinson Disease
Intervention: Procedure: Stimulation procedure
Outcome Measures: The severe adverse events rate within the procedure;   Improvement in tremor symptoms during the procedure
5 Not yet recruiting Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation
Condition: Essential Tremor
Intervention: Device: Cathodal cerebellar transcranial direct current stimulation
Outcome Measures: Change from baseline in tremor amplitude on clinical rating scale;   Change from baseline in tremor amplitude on accelerometric recording;   Change from baseline in tremor amplitude on electromyographic recordings;   Change from baseline in tremor amplitude on digitized tablet;   Change from baseline of amplitude of motor evoked potentials elicited by TMS
6 Recruiting Continuous Tremor Assessment During Daily Activities
Condition: Essential Tremor
Intervention: Device: Kinesia HomeView
Outcome Measures: Clinical Global Impression-Change Scale score;   Clinical Global Impression-Severity Scale Score;   Washington Heights Inwood Genetic Study of Essential Tremor (WHIGET) Tremor Rating Scale;   Quality of Life in Essential Tremor Questionnaire
7 Recruiting Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor
Conditions: Parkinson's Disease;   Tremor
Interventions: Device: Up to 3 mA, 60 us, 130 Hz deep brain stimulation;   Device: Empirical unblinded deep brain stimulation programming
Outcome Measures: Change from baseline United Parkinsons Disease Rating Scale Part III at 3 months;   Change from baseline United Parkinsons Disease Rating Scale Part III at 6 months;   Change from baseline United Parkinsons Disease Rating Scale Part III at 12 months;   Change from baseline Fahn Tolosa Marin tremor scale at 3 months;   Change from baseline Fahn Tolosa Marin tremor scale at 6 months;   Change from baseline Fahn Tolosa Marin tremor scale at 12 months;   Change from baseline ON-OFF diary at 3 months;   Change from baseline ON-OFF diary at 6 months;   Change from baseline ON-OFF diary at 12 months;   Adverse events;   Change from baseline Short form 36 at 3 months;   Change from baseline Short form 36 at 6 months;   Change from baseline Short form 36 at 12 months;   Change from baseline Parkinsons Disease Quality of Life 39 at 3 months;   Change from baseline Parkinsons Disease Quality of Life 39 at 6 months;   Change from baseline Parkinsons Disease Quality of Life 39 at 12 months;   Change from baseline L-dopa equivalent dose at 3 months;   Change from baseline L-dopa equivalent dose at 6 months;   Change from baseline L-dopa equivalent dose at 12 months;   Change from baseline neuropsychological battery at 3 months;   Change from baseline neuropsychological battery at 6 months;   Change from baseline neuropsychological battery at 12 months;   Change from baseline verbal fluency at 3 months;   Change from baseline verbal fluency at 6 months;   Change from baseline verbal fluency at 12 months;   Change from baseline Mini-International Neuropsychiatric Interview Plus at 3 months;   Change from baseline Mini-International Neuropsychiatric Interview Plus at 6 months;   Change from baseline Mini-International Neuropsychiatric Interview Plus at 12 months;   Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 3 months;   Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 6 months;   Change from baseline United Parkinsons Disease Rating Scale parts I, II, IV, V at 12 months;   Change from baseline Abnormal Involuntary Movement Scale at 3 months;   Change from baseline Abnormal Involuntary Movement Scale at 6 months;   Change from baseline Abnormal Involuntary Movement Scale at 12 months
8 Recruiting Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor
Conditions: Parkinson's Disease;   Essential Tremor
Intervention:
Outcome Measures: Fractional anisotropy (FA) in the caudal portion of substantia nigra;   Comparison between MRI and ultrasonography
9 Unknown  Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
Condition: Essential Tremor
Interventions: Drug: pramipexole;   Drug: placebo
Outcome Measures: Improvement in tremor severity;   Improvement in quality of life;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability
10 Recruiting Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates
Condition: Essential Tremor
Intervention:
Outcome Measures: Phase 1: To objectively determine the rate of ethanol responders vs. non-responders in a prospective sample of ET patients.;   Phase 2: To evaluate changes of SICI in responding vs. non-responding ET patients during a continuous ethanol administration;   Phase 1: To correlate spirographic and clinical response in both hands with breath-alcohol-levels, acquired using a Breathalyzer at constant intervals after ethanol administration.;   Phase 2: To evaluate changes additional TMS measures between groups
11 Unknown  The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
Conditions: Multiple Sclerosis;   Tremor
Intervention: Drug: Botulinum Toxin Type A
Outcome Measures: A decrease in tremor;   The safety profile of Botulinum Toxin in MS patients
12 Recruiting Assessment of Tremor Using SNUMAP Motion Sensing System
Condition: Tremor
Intervention: Device: SNUMAP
Outcome Measure: 3-D Accelerometric and gyroscope variables measured
13 Recruiting Radiosurgery for Drug Resistant Invalidating Tremor
Condition: Severe Upper Limb Tremor Refractory to Medical Therapy
Intervention: Radiation: Radiosurgical thalamotomy
Outcome Measures: Tremor control (improvement in FTMTRS and/or UPDRS motor);   Targeting methodology validation (the lesions position, if present, will be compared to the treatment plan target position, deviations will be registered).;   The treatment safety will be evaluated. Toxicity will be registered according to NCI-CTCAE v3.
14 Recruiting ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
Condition: Essential Tremor
Interventions: Device: Transcranial ExAblate;   Device: Sham Transcranial ExAblate
Outcome Measures: Severity of Device and Procedure related complications;   Effectiveness of of the ExAblate Transcranial MRgFUS treatment
15 Recruiting Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Conditions: Spasmodic Dysphonia;   Voice Tremor
Intervention: Drug: Sodium oxybate
Outcome Measure: Brain Activity
16 Unknown  Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor
Condition: Parkinsonian Syndromes
Intervention: Drug: 123 I - ALTROPANE®
Outcome Measures: To evaluate the diagnostic accuracy of a single dose of 123 I-ALTROPANE® as an imaging agent to aid in the diagnosis of Parkinsonian syndromes (PS) in subjects with upper extremity tremor for less than 2 years.;   To evaluate the safety of 123 I-ALTROPANE® in subjects with upper extremity tremor for less than 2 years.
17 Recruiting Deep Brain Stimulation Surgery for Movement Disorders
Conditions: Parkinson's Disease;   Essential Tremor;   Dystonia
Intervention: Procedure: Deep Brain Stimulation
Outcome Measures: Change in UPDRS III scale, Burke-Fahn-Marsden (BFM) scale, and Tremor Rating Scale before and 1 year after treatment.;   Levels of effective drug therapy before/after surgery;   Radiographic correlation of DBS electrode position and clinical changes;   Neurophysiological mechanisms of DBS and motor/cognitive function in basal ganglia
18 Not yet recruiting Local Fields Potentials Recorded From Deep Brain Stimulating Electrodes
Conditions: Parkinson's Disease;   Essential Tremor;   Dystonia
Intervention:
Outcome Measure: Recording and evaluating LFPs from DBS electrodes in patients with Parkinson's Disease, Essential Tremor or Dystonia
19 Recruiting Cannabis and Parkinson's Disease Tremor: A Natural History Study
Condition: Parkinson's Disease
Intervention:
Outcome Measure: Percent reduction in tremor as measured by Opal movement sensor
20 Recruiting Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders, PD,Essential Tremor, (ET),Cortical Basal Degeneration, (CBD),Multiple Systems Atrophy (MSA), Magnetoencephalography
Conditions: Essential Tremor;   Multiple System Atrophy;   Corticobasal Degeneration;   Supranuclear Palsy, Progressive
Intervention:
Outcome Measures: Focal oscillatory activity;   Spectral coherence:;   Spectral Granger analysis:;   Reactivity:;   Complex network analysis: